1.80
+0.07(+4.05%)
Currency In USD
| Previous Close | 1.73 |
| Open | 1.77 |
| Day High | 1.84 |
| Day Low | 1.75 |
| 52-Week High | 4.74 |
| 52-Week Low | 1.6 |
| Volume | 178,524 |
| Average Volume | 147,185 |
| Market Cap | 201.7M |
| PE | -4.62 |
| EPS | -0.39 |
| Moving Average 50 Days | 2.24 |
| Moving Average 200 Days | 2.91 |
| Change | 0.07 |
If you invested $1000 in Waldencast plc (WALD) since IPO date, it would be worth $179.7 as of August 18, 2025 at a share price of $1.77. Whereas If you bought $1000 worth of Waldencast plc (WALD) shares 3 years ago, it would be worth $196.65 as of August 18, 2025 at a share price of $1.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
GlobeNewswire Inc.
Jul 23, 2025 10:45 AM GMT
Acquisition strengthens Obagi Medical’s product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWI
Waldencast plc Announces First Quarter Fiscal 2025 Results Conference Call and Webcast
GlobeNewswire Inc.
May 06, 2025 8:05 PM GMT
LONDON, May 06, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its First Quarter Fiscal 2025 conference call and webcast. As previously announced,
Obagi Medical Announces the Launch of Retinol + PHA Refining Night Cream
GlobeNewswire Inc.
Apr 22, 2025 12:30 PM GMT
A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking Complexion NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi